Filing Details

Accession Number:
0000950170-24-003984
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-01-11 17:11:49
Reporting Period:
2024-01-09
Accepted Time:
2024-01-11 17:11:49
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1658551 Amylyx Pharmaceuticals Inc. AMLX () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1235598 M James Frates C/O Amylyx Pharmaceuticals, Inc.
43 Thorndike Street
Cambridge MA 02141
Chief Financial Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2024-01-09 2,716 $16.33 112,035 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 11,072 Indirect By Trust
Footnotes
  1. Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.
  2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.18 to $16.70. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
  3. Shares held by the FRATES FAMILY 2013 IRREV TRUST, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.